Avalyn Pharma priced a $300 million IPO to fund late-stage studies of inhaled respiratory drugs, joining a wave of biotech listings focused on respiratory and immunology-adjacent franchises. Meanwhile, Seaport Therapeutics and Hemab Therapeutics also priced IPOs, adding more than $850 million combined across the debut set. Avalyn’s proceeds are expected to support development of inhaled versions of approved pulmonary fibrosis therapies, with data from mid-stage studies anticipated in 2027. Seaport and Hemab’s debuts extend a broader market window for new biotech listings. For biotech finance, the clustered IPO activity suggests investor appetite remains strongest where clinical programs can connect directly to established treatment paradigms or measurable registrational endpoints.